drugset / Trial / NCT01427842

Dose Enhancement of Vancomycin IN Everyday Patients

NCT01427842

Phase 2 Unknown 100 enrolled The Canberra Hospital
RandomizedSingle-groupSingle-blindTreatment

Summary

Current Australian guidelines for vancomycin commonly underdoses individuals particularly in the first 48 hours. The aim of the trial is to compare two dosing regimens; the current Australian guidelines versus a more appropriately modeled pharmacokinetic based regimen with the overall aim of developing a new vancomycin dosing strategy that will enable patients to have more individualised and therapeutically efficacious treatment. The hypothesis is that dosing vancomycin according to a pharmacokinetically modeled regimen increases the likelihood of achieving therapeutic trough levels of vancomycin within the first 48 hours (or at steady state, whichever is sooner) compared to dosing vancomycin according to the current Antibiotic guidelines.

Timeline

Start
2011-08
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Vancomycin Other / unclassified

Indications

No indication recorded.